Davis KL, Kaye JA, Masters ET, Iyer S. Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Curr Oncol. 2018 Feb;25(1):e40-9. doi: 10.3747/co.25.3723
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Patel JC, Taylor SM, Juliao PC, Parobek CM, Janko M, Gonzalez LD, Ortiz L, Padilla N, Tshefu AK, Emch M, Udhayakumar V, Lindblade K, Meshnick SR. Genetic evidence of importation of drug-resistant plasmodium falciparum to Guatemala from the Democratic Republic of the Congo. Emerg Infect Dis. 2014 Jun;20(6):932-40. doi: 10.3201/eid2006.131204
McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.